Arena Pharmaceuticals Inc (NASDAQ: ARNA ) and VIVUS (NASDAQ: VVUS ) in early 2012 as each company headed into their regulatory reviews with the U.S. Food and Drug Administration, or FDA, for their respective obesity medications. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) stock performance was -2.84% in last session and finished the day at $6.49. Traded volume was 6.83million shares in the last session and the average volume of the stock remained 5.74million shares. The beta of the stock remained -0.63. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) insider ownership is 10.47%.
Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) approved a Supplemental New Drug Application (sNDA) for Eliquis (apixaban) for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery. Pfizer Inc. (NYSE:PFE) rose 0.35 percent to $31.23 Friday on volume of 27.11million shares. The intra-day range of the stock was $30.83 to $31.43. Pfizer Inc. (NYSE:PFE) has a market capitalization of $199.67billion.
Turning that understanding into a medicine hasn’t been easy. Merck & Co. Inc. (NYSE:MRK), the second-biggest U.S. drugmaker by sales, ended development of such a treatment for Parkinson’s disease last year after late-stage testing suggested it didn’t work. And Japan’s Kyowa had to postpone plans to bring its drug to the U.S. market. Merck & Co., Inc. (NYSE:MRK)’s stock on Mar 14, 2014 reported a decrease of -0.16% to the closing price of $55.70. Its fifty two weeks range is $43.51 -$57.65. The total market capitalization recorded $163.79billion. The overall volume in the last trading session was 12.07million shares. In its share capital, MRK has 2.93billion outstanding shares.
Teva Pharmaceutical Industries Ltd. (ADR) (NYSE:TEVA) was accused of paying Michael Reinstein, a psychiatrist who has figured into two ProPublica investigations, to overprescribe a risky antipsychotic. On Friday, shares of Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) advanced 1.92% to close the day at $48.88. Company return on investment (ROI) is 4.90% and its monthly performance is recorded as 11.73%. Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) quarterly revenue growth is 23.37%.